Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5205818
Max Phase: Preclinical
Molecular Formula: C30H29ClF3N3O3
Molecular Weight: 572.03
Associated Items:
ID: ALA5205818
Max Phase: Preclinical
Molecular Formula: C30H29ClF3N3O3
Molecular Weight: 572.03
Associated Items:
Canonical SMILES: CC(=O)/C=C/[C@H](CCc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)Nc1ccc(Cl)cc1C(F)(F)F
Standard InChI: InChI=1S/C30H29ClF3N3O3/c1-20(38)12-15-24(16-13-21-8-4-2-5-9-21)35-28(39)27(18-22-10-6-3-7-11-22)37-29(40)36-26-17-14-23(31)19-25(26)30(32,33)34/h2-12,14-15,17,19,24,27H,13,16,18H2,1H3,(H,35,39)(H2,36,37,40)/b15-12+/t24-,27+/m1/s1
Standard InChI Key: NRYGNORBOZCGEL-CHUVPVKVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 572.03 | Molecular Weight (Monoisotopic): 571.1850 | AlogP: 6.35 | #Rotatable Bonds: 11 |
Polar Surface Area: 87.30 | Molecular Species: NEUTRAL | HBA: 3 | HBD: 3 |
#RO5 Violations: 2 | HBA (Lipinski): 6 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 12.19 | CX Basic pKa: | CX LogP: 6.71 | CX LogD: 6.71 |
Aromatic Rings: 3 | Heavy Atoms: 40 | QED Weighted: 0.23 | Np Likeness Score: -0.61 |
1. Previti S, Ettari R, Calcaterra E, Di Chio C, Ravichandran R, Zimmer C, Hammerschmidt S, Wagner A, Bogacz M, Cosconati S, Schirmeister T, Zappalà M.. (2022) Development of Urea-Bond-Containing Michael Acceptors as Antitrypanosomal Agents Targeting Rhodesain., 13 (7.0): [PMID:35859868] [10.1021/acsmedchemlett.2c00084] |
Source(1):